Bayer

Andrea Germanos, staff writer
Demonstrators walk with placards during a march for agroecology and civil resistance against U.S. seed and pesticide maker Monsanto on May 20, 2017 in Bordeaux, southwestern France.
The deal includes $1.25 billion to cover potential future settlements.
Jake Johnson, staff writer
The World Health Organization's cancer research arm classified glyphosate—the...
Andrea Germanos, staff writer
Brad Rose looks at rows of soybean plants that show signs of having been affected by Dicamba use on Aug 9, 2017
"This verdict is just the tip of the iceberg."

Further

Up there in the annals of multinational corporations doing heinous things in the name of obscene profits comes the German-based Bayer's response to India ending the pharma giant's monopoly for a pricey new anti-cancer drug, thus allowing a small Indian company to make a generic version that poor sick people can afford. A year of Bayer's Nexavar costs $96,000 in the U.S. and $69,000 in India, 41 times the per capita income; India's Natco Ltd. made it for $177 a year. Outraged Bayer officials...